Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients

British Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2004, Pages 352-358

  Agersø, Henrik ^a,c   Larsen, Lotte Seiding ^a   Riis, Anders ^b   Lövgren, Ulf ^c   Karlsson, Mats O ^d   Senderovitz, Thomas ^a  

^a Experimental Medicine   (Denmark)

^b Biometrics   (Denmark)

^c Ferring Pharmaceuticals AS   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

DDAVP; Desmopressin; Nonlinear mixed effects; NONMEM; Pharmacokinetics; Renal impairment; Urinary excretion

Indexed keywords

DESMOPRESSIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SIDE EFFECT; WEIGHT GAIN;

AGED; DEAMINO ARGININE VASOPRESSIN; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL AGENTS;

EID: 4744337511     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02175.x     Document Type: Article

References (34)

1. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-63.
2. Asplund R, Sundberg B, Bengtsson P. Desmopressin for the treatment of nocturnal polyuria in the elderly: a dose titration study. Br J Urol 1998; 82: 642-6.
3. Birkasova M, Birkas O, Flynn MJ, Cort JH. Desmopressin in the management of nocturnal enuresis in children: a double-blind study. Pediatrics 1978; 62: 970-4.
4. Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br J Urol 1982; 54: 252-5.
5. Evans JH, Meadow SR. Desmopressin for bed wetting: length of treatment, vasopressin secretion, and response. Arch Dis Child 1992; 67: 184-8.
6. Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 1992; 10: 98-104.
7. Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. BMJ (Clin Res Ed) 1983; 287: 1665-7.
8. Larsson G, Victor A. Micturition patterns in a healthy female population, studied with a frequency/volume chart. Scand J Urol Nephrol Suppl 1988; 114: 53-7.
9. Asplund R, Aberg HE. Micturition habits of older people. Voiding frequency and urine volumes. Scand J Urol Nephrol 1992; 26: 345-9.
10. Brocklehurst JC, Fry J, Griffiths LL, Kalton G. Dysuria in old age. J Am Geriatr Soc 1971; 19: 582-92.
11. Cannon A, Carter PG, McConnell AA, Abrams P. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int 1999; 84: 20-4.
12. Chancellor MB, Atan A, Rivas DA, Watanabe T, Tai HL, Kumon H. Beneficial effect of intranasal desmopressin for men with benign prostatic hyperplasia and nocturia: preliminary results. Techn Urol 1999; 5: 191-4.
13. Eckford SD, Carter PG, Jackson SR, Penney MD, Abrams P. An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia. Br J Urol 1995; 76: 459-63.
14. Eckford SD, Swami KS, Jackson SR, Abrams PH. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994; 74: 733-5.
15. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53: 1270-5.
16. Bernstein SA, Williford SL. Intranasal desmopressin-associated hyponatremia: a case report and literature review. J Fam Pract 1997; 44: 203-8.
17. Odeh M, Oliven A. Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis. J Clin Pharmacol 2001; 41: 582-4.
18. Mulder WJ, Hillen HF. Renal function and renal disease in the elderly: part I. European Journal of Internal Medicine 2001; 12: 86-97.
19. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol 1993; 38: 177-82.
20. Aunsholt NA, Vilhardt H, Schmidt EB. Plasma half-life of DDAVP in uraemic patients. Acta Pharmacol Toxicol 1986; 59: 332-3.
21. Ruzicka H, Bjorkman S, Lethagen S, Sterner G. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol 2003; 92: 137-42.
22. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206-8.
23. Lundin S, Melin P, Vilhardt H. Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat. Acta Endocrinologica 1985; 106: 179-83.
24. Mazzachi BC, Peak MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffé creatine assays in plasma and serum and early morning urine. Clin Lab 2000; 46(1-2): 53-5.
25. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Report 1970; 54: 225-35.
26. Beal SL, Sheiner LB. NONMEM Users Guide. University of California, San Francisco: NONMEM Project Group, 1998.
27. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998; 26: 207-46.
28. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Meth Programs Biomed 1999; 58: 51-64.
29. Callreus T, Odeberg J, Lundin S, Hoglund P. Indirect-response modeling of desmopressin at different levels of hydration. J Pharmacokinet Biopharm 1999; 27: 513-29.
30. Fjellestad-Paulsen A, d'Agay-Abensour L, Hoglund P, Rambaud JC. Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. Eur J Clin Pharmacol 1996; 50: 491-5.
31. Patterson SE, Cohn VH. Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol 1984; 33: 711-6.
32. Uchida N, Kurata N, Shimada K, Nishimura Y, Yasuda K, Hashimoto M, Uchida E, Yasuhara H. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 1995; 68: 431-9.
33. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003; 73: 427-34.
34. Bennett WM. Guide to drug dosage in renal failure. Clin Pharmacokinet 1988; 15: 326-54.